I[NTRODUCTION]{.smallcaps} {#sec1-1}
==========================

Though guidelines do not recommend the screening of thyroid diseases in cases of Immune thrombocytopenia (ITP), numerous case reports would suggest that patients with ITP and concurrent hyperthyroidism, would respond to control of thyroid disease rather than the standard ITP treatment.

C[ASE REPORT]{.smallcaps} {#sec1-2}
=========================

We report a case of ITP in a known case of hyperthyroidism in a 36-year-old female of Indian origin. She initially presented to the outpatient department with asymptomatic thrombocytopenia.

However, she had a history of bleeding gums, menorrhagia, and ecchymotic patches on all over body 4 months back. These complaints were associated with weakness and easy fatigability for which she had consulted a private physician. Laboratory reports were suggestive of serum thyroid-stimulating hormone (TSH): 0.001 microIU/mL (normal range: 0.35--5.5 microIU/mL), hemoglobin: 4.8 g%, white blood cells 5000/μL, and platelet: 36,000/μL. Considering anemia due to an acute bleeding episode, she was given 2-pack cell volume. After a week, she underwent laboratory investigations in which thrombocytopenia was persistent. She consulted a hematologist for that report and underwent investigations for thrombocytopenia. All investigations turned out to be negative (serum lactate dehydrogenase, direct Coombs test (DCT) and indirect DCT = Negative.) Even though reports were suggestive of hyperthyroidism, antithyroid medications (carbimazole 10 mg once a day) were stopped. She was started on steroids; however, there was no improvement in platelet counts. After 3 months of unsatisfactory treatment, she presented at our center. On general examination, the patient was conscious, cooperative, and well oriented to time, place, and person. Pulse rate was 110/min with the blood pressure of 120/70 mmHg. There was no edema, icterus, cyanosis, clubbing, and lymphadenopathy. On thyroid gland examination, there was no thyroid enlargement and bruits present. Per abdomen examination spleen and liver were not palpable and the rest of systemic examinations were unremarkable.

On admission, laboratory investigations revealed: hemoglobin 13.6 g/dL, total leukocyte count 7800/μL, platelet count 21,000/μL. Serum TSH 0.01 mIU/L (normal range: 0.35--5.5 mIU/L), serum free T3 8.48 pmol/L (normal range: 3.542--6.468 pmol/L), and serum free T4 37.97 pmol/L (normal range 11.5--22.7 pmol/L). Urine routine examination, liver function test, and renal function test were within normal limits. Peripheral smear did not showmalarial parasite. Dengue nonspecific antigen 1, Ig-G, and Ig-M were negative. Human Immunodeficiency Virus (HIV), HbsAg, hepatitis C virus were negative Antinuclear antibody profile was negative ruling out autoimmune causes. Bone marrow examination revealed normal functioning marrow. However, we restarted carbimazole 10 mg three times a day which had been kept on hold, and steroids were tapered off. After starting antithyroid medications, her platelet counts gradually improved. During subsequent follow-up, her thyroid function tests and platelet counts became normal. The trend of her platelet counts and thyroid function tests is summarized in \[Tables [1](#T1){ref-type="table"} and [2](#T2){ref-type="table"}\].

###### 

Trend of thyroid function test and platelet counts before starting antithyroid therapy

  Date             Serum TSH (normal range: 0.35-5.5 mIU/L)   Free T3 (normal range: 3.542-6.468 pmol/L)   Free T4 (normal range: 11.5-22.7 pmol/L)   Platelet counts (normal range: 150,000-450,000/µL)   Treatment received   Steroid dose
  ---------------- ------------------------------------------ -------------------------------------------- ------------------------------------------ ---------------------------------------------------- -------------------- ---------------------------------------------------------------------------------------------------------------------------------------
  March 08, 2016   0.001                                      7.3                                          29.5                                       36,000                                               FFP, PCV, steroids   Methylprednisolone 1 g/day for 3 days then prednisolone 70 mg/day (1 mg/kg/day) for 1^st^ month then tapered. 5 mg reduced every week
  March 16, 2016   0.06                                       8.12                                         30.1                                       12,000                                               Steroids             
  April 08, 2016   \-                                         \-                                           \-                                         73,000                                               Steroids             
  May 05, 2016     0.08                                       \-                                           \-                                         45,000                                               Steroids             
  June 01, 2016    \-                                         \-                                           \-                                         121,000                                              Steroids             
  July 08, 2016    0.05                                       12.2                                         35.3                                       34,000                                               Steroids             
  July 14, 2016    0.01                                       8.48                                         37.97                                      21,000                                               Carbimazole          

TSH: Thyroid-stimulating hormone, T3: Triiodothyronine, T4: Thyroxine, FFP: Fresh frozen plasma, PCV: Pack cell volume

###### 

Trend of thyroid function test and platelet counts after starting antithyroid therapy

  Date                 Serum TSH (normal range: 0.35-5.5 mIU/L)   Free T3 (normal range: 3.542-6.468 pmol/L)   Free T4 (normal range: 11.5-22.7 pmol/L)   Platelet counts (normal range: 150,000-450,000/µL)   Treatment received   Dose of carbimazole
  -------------------- ------------------------------------------ -------------------------------------------- ------------------------------------------ ---------------------------------------------------- -------------------- ---------------------
  July 17, 2016        \-                                         \-                                           \-                                         30,000                                               Carbimazole          30 mg
  August 08, 2016      0.02                                       3.90                                         13.53                                      292,000                                              Carbimazole          
  September 19, 2016   0.13                                       4.32                                         14.33                                      308,000                                              Carbimazole          
  October 25, 2016     0.6                                        5.01                                         18.25                                      210,000                                              Carbimazole          
  December 05, 2016    0.7                                        5.4                                          20.72                                      249,000                                              Carbimazole          
  January 06, 2017     \-                                         4.3                                          17.85                                      297,000                                              Carbimazole          
  February 13, 2017    \-                                         \-                                           22.45                                      271,000                                              Carbimazole          

TSH: Thyroid-stimulating hormone, T3: Triiodothyronine, T4: Thyroxine

D[ISCUSSION]{.smallcaps} {#sec1-3}
========================

Coexistence of ITP and hyperthyroidism is a well-documented but not a well-understood association. The association of these two diseases can be explained by the theory of the production of two kinds of antibodies (platelet-associated IgG, antithyroid antibodies \[Microsomal and thyroglobulin antibodies\]) against platelets and TSH receptor \[[@ref1]\]. In addition to this, shorter platelet lifespan, which is metabolic in nature rather than immunogenic, in patients with hyperthyroidism and increased reticuloendothelial phagocytic activity are also postulated as a mechanism for thrombocytopenia in a case of hyperthyroidism \[[@ref2][@ref3]\]. The presentation of this association varies from case to case. It can present with a new onset of thrombocytopenia without life-threatening symptoms in a patient with preexisting hyperthyroidism, or it can present with a life-threatening thyrotoxic crisis which mimics sepsis in a known case of stable ITP \[[@ref4][@ref5]\]. In fact, studies show that autoimmune thrombocytopenia, in the course of thyroid disease, is far more prevalent than vice versa \[[@ref1]\].

Although hyperthyroidism is known to shorten the platelet survival by enhancing reticuloendothelial activity, the resultant thrombocytopenia is usually mild-to-moderate \[[@ref3]\]. Therefore, this mechanism cannot explain the severe thrombocytopenia of the present case. The severity of the thrombocytopenia and its responsiveness to antithyroid medication strongly support the first view that both disorders stemmed from a common autoimmunity. A similar response was seen in a case of ITP with Graves, whereby dose adjustment of methimazole normalized the thyroid function as well as spontaneous recovery of platelet count which had fallen due to irregular adherence to antithyroid medication \[[@ref4]\]. However, in our case-patient was already prescribed steroids for ITP for 2 months, but the failure of the standard therapy to improve platelet counts prompted us to look for other therapeutic options. After correcting thyroid function with antithyroid medication, platelet count raised without concurrent steroid supplementation. This suggests that in a patient of hyperthyroidism with ITP, correction of the hyperthyroidism plays a role in correcting the immune system imbalance which impairs not only the thyroid function but also the platelet antigen response. Despite more than 160 cases of hyperthyroidism associated with ITP that have been reported, the American society of hematology Guidelines and British guidelines do not recommend screening of thyroid diseases in cases of ITP \[[@ref6][@ref7][@ref8]\]. This is might be because of lack of clarity of the exact mechanism and association.
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